Top 5 Stocks to Buy Now
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free LENZ Stock Alerts

LENZ Therapeutics (LENZ) Competitors

LENZ Therapeutics logo
$6.15 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$6.09 -0.06 (-0.98%)
As of 06/18/2026 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LENZ vs. TBPH, ABUS, LBRX, ETON, and JANX

Should you buy LENZ Therapeutics stock or one of its competitors? MarketBeat compares LENZ Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENZ Therapeutics include Theravance Biopharma (TBPH), Arbutus Biopharma (ABUS), LB Pharmaceuticals (LBRX), Eton Pharmaceuticals (ETON), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.

How does LENZ Therapeutics compare to Theravance Biopharma?

LENZ Therapeutics (NASDAQ:LENZ) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Theravance Biopharma has a net margin of 104.34% compared to LENZ Therapeutics' net margin of -519.30%. Theravance Biopharma's return on equity of 18.84% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-519.30% -46.82% -43.32%
Theravance Biopharma 104.34%18.84%10.94%

In the previous week, Theravance Biopharma had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Theravance Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Theravance Biopharma has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M10.10-$82.13M-$3.60N/A
Theravance Biopharma$107.46M7.95$105.89M$2.207.54

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LENZ Therapeutics presently has a consensus target price of $29.80, suggesting a potential upside of 384.55%. Theravance Biopharma has a consensus target price of $21.40, suggesting a potential upside of 29.07%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Theravance Biopharma
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.29

LENZ Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Summary

Theravance Biopharma beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Arbutus Biopharma has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$14.08M63.84-$33.50M$0.835.48
LENZ Therapeutics$19.09M10.10-$82.13M-$3.60N/A

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 9.89%. LENZ Therapeutics has a consensus price target of $29.80, indicating a potential upside of 384.55%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Arbutus Biopharma has a net margin of 83.95% compared to LENZ Therapeutics' net margin of -519.30%. Arbutus Biopharma's return on equity of 129.32% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma83.95% 129.32% 112.24%
LENZ Therapeutics -519.30%-46.82%-43.32%

In the previous week, LENZ Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 1 mentions for LENZ Therapeutics and 0 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.00 equaled LENZ Therapeutics'average media sentiment score.

Company Overall Sentiment
Arbutus Biopharma Neutral
LENZ Therapeutics Neutral

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Arbutus Biopharma has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Summary

Arbutus Biopharma beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to LB Pharmaceuticals?

LENZ Therapeutics (NASDAQ:LENZ) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

LB Pharmaceuticals has lower revenue, but higher earnings than LENZ Therapeutics. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M10.10-$82.13M-$3.60N/A
LB PharmaceuticalsN/AN/A-$25.20M-$1.73N/A

In the previous week, LB Pharmaceuticals had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 3 mentions for LB Pharmaceuticals and 1 mentions for LENZ Therapeutics. LB Pharmaceuticals' average media sentiment score of 0.24 beat LENZ Therapeutics' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LB Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

LB Pharmaceuticals has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LB Pharmaceuticals' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-519.30% -46.82% -43.32%
LB Pharmaceuticals N/A N/A N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

LENZ Therapeutics currently has a consensus target price of $29.80, suggesting a potential upside of 384.55%. LB Pharmaceuticals has a consensus target price of $38.40, suggesting a potential upside of 27.86%. Given LENZ Therapeutics' higher possible upside, equities research analysts plainly believe LENZ Therapeutics is more favorable than LB Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
LB Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

LB Pharmaceuticals beats LENZ Therapeutics on 9 of the 14 factors compared between the two stocks.

How does LENZ Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Eton Pharmaceuticals had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 1 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 beat Eton Pharmaceuticals' score of -0.03 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eton Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LENZ Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Eton Pharmaceuticals has a net margin of -1.70% compared to LENZ Therapeutics' net margin of -519.30%. Eton Pharmaceuticals' return on equity of -5.68% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals-1.70% -5.68% -1.49%
LENZ Therapeutics -519.30%-46.82%-43.32%

Eton Pharmaceuticals presently has a consensus price target of $41.00, suggesting a potential upside of 26.23%. LENZ Therapeutics has a consensus price target of $29.80, suggesting a potential upside of 384.55%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Eton Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eton Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eton Pharmaceuticals has higher revenue and earnings than LENZ Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eton Pharmaceuticals$79.95M11.13-$4.60M-$0.07N/A
LENZ Therapeutics$19.09M10.10-$82.13M-$3.60N/A

Eton Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Summary

Eton Pharmaceuticals beats LENZ Therapeutics on 10 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Janux Therapeutics currently has a consensus target price of $45.85, suggesting a potential upside of 222.41%. LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 384.55%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.60
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

LENZ Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M86.71-$113.62M-$1.84N/A
LENZ Therapeutics$19.09M10.10-$82.13M-$3.60N/A

In the previous week, Janux Therapeutics and Janux Therapeutics both had 1 articles in the media. Janux Therapeutics' average media sentiment score of 1.88 beat LENZ Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
LENZ Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Janux Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Janux Therapeutics' return on equity of -12.93% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -12.93% -12.23%
LENZ Therapeutics -519.30%-46.82%-43.32%

Janux Therapeutics has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Summary

Janux Therapeutics beats LENZ Therapeutics on 11 of the 16 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LENZ vs. The Competition

Export
MetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$192.83M$3.41B$6.65B$12.60B
Dividend YieldN/A2.32%2.68%5.81%
P/E Ratio-1.7119.7324.7524.42
Price / Sales10.10320.32529.30111.09
Price / CashN/A56.5427.9237.84
Price / Book0.688.1510.816.60
Net Income-$82.13M$23.91M$3.57B$337.10M
7 Day Performance-9.16%2.57%0.72%0.83%
1 Month Performance-18.22%0.69%0.41%2.25%
1 Year Performance-79.46%55.09%29.34%36.14%

LENZ Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LENZ
LENZ Therapeutics
3.1728 of 5 stars		$6.15
flat		$29.80
+384.6%		-79.5%$192.83M$19.09MN/A110
TBPH
Theravance Biopharma
2.693 of 5 stars		$16.49
+1.2%		$21.83
+32.4%		+56.0%$850.06M$107.46M7.50110
ABUS
Arbutus Biopharma
1.1189 of 5 stars		$4.25
+0.2%		$5.00
+17.6%		+32.7%$839.55M$14.08M5.1290
LBRX
LB Pharmaceuticals
2.0565 of 5 stars		$29.27
-0.4%		$38.40
+31.2%		N/A$839.46MN/AN/A16
ETON
Eton Pharmaceuticals
4.1717 of 5 stars		$30.53
+1.9%		$41.00
+34.3%		+139.4%$836.22M$79.95MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel